Korro Bio (NASDAQ:KRRO) Posts Earnings Results, Misses Expectations By $3.39 EPS

Korro Bio (NASDAQ:KRRO) issued its quarterly earnings data on Thursday. The company reported ($5.32) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.93) by ($3.39), FiscalAI reports. Korro Bio had a negative return on equity of 99.63% and a negative net margin of 1,834.48%.The company had revenue of $1.29 million for the quarter, compared to analysts’ expectations of $0.43 million.

Korro Bio Trading Up 11.3%

Shares of NASDAQ:KRRO traded up $1.30 during trading on Friday, reaching $12.80. The company had a trading volume of 1,096,891 shares, compared to its average volume of 176,681. The company has a fifty day moving average of $10.99 and a two-hundred day moving average of $20.18. The stock has a market capitalization of $120.58 million, a P/E ratio of -1.03 and a beta of 2.98. Korro Bio has a 12 month low of $5.20 and a 12 month high of $55.89.

Insider Buying and Selling

In other news, major shareholder Edward T. Mathers purchased 207,100 shares of the stock in a transaction on Tuesday, March 10th. The shares were acquired at an average price of $11.11 per share, for a total transaction of $2,300,881.00. Following the completion of the transaction, the insider directly owned 1,297,893 shares of the company’s stock, valued at approximately $14,419,591.23. This trade represents a 18.99% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through this link. Also, major shareholder Forest Baskett purchased 207,100 shares of the company’s stock in a transaction on Tuesday, March 10th. The shares were purchased at an average cost of $11.11 per share, with a total value of $2,300,881.00. Following the purchase, the insider owned 1,297,893 shares of the company’s stock, valued at approximately $14,419,591.23. The trade was a 18.99% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Insiders bought 1,656,800 shares of company stock valued at $18,407,048 in the last three months. 4.60% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Korro Bio

Institutional investors have recently modified their holdings of the company. Geode Capital Management LLC lifted its position in Korro Bio by 10.8% in the 2nd quarter. Geode Capital Management LLC now owns 155,387 shares of the company’s stock worth $1,941,000 after buying an additional 15,166 shares during the last quarter. Raymond James Financial Inc. grew its position in Korro Bio by 357.6% during the second quarter. Raymond James Financial Inc. now owns 83,392 shares of the company’s stock valued at $1,042,000 after acquiring an additional 65,170 shares during the last quarter. Bank of America Corp DE raised its stake in shares of Korro Bio by 520.0% during the second quarter. Bank of America Corp DE now owns 28,156 shares of the company’s stock worth $352,000 after acquiring an additional 23,615 shares in the last quarter. CWM LLC raised its stake in shares of Korro Bio by 391.4% during the third quarter. CWM LLC now owns 2,693 shares of the company’s stock worth $129,000 after acquiring an additional 2,145 shares in the last quarter. Finally, Emerald Mutual Fund Advisers Trust bought a new stake in shares of Korro Bio in the 3rd quarter worth approximately $2,821,000. 13.18% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

KRRO has been the topic of a number of analyst reports. Raymond James Financial raised shares of Korro Bio from a “market perform” rating to an “outperform” rating and set a $23.00 target price on the stock in a report on Friday. Chardan Capital upgraded shares of Korro Bio from a “neutral” rating to a “buy” rating and set a $15.00 price target for the company in a research report on Thursday, January 29th. Clear Str raised shares of Korro Bio from a “hold” rating to a “strong-buy” rating in a report on Wednesday, February 18th. William Blair upgraded Korro Bio from a “market perform” rating to an “outperform” rating in a research report on Tuesday, February 17th. Finally, Wall Street Zen lowered Korro Bio from a “hold” rating to a “sell” rating in a research note on Saturday, December 13th. One investment analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $44.50.

Key Korro Bio News

Here are the key news stories impacting Korro Bio this week:

• Positive Sentiment: Raymond James upgraded KRRO from “market perform” to “outperform” and set a $23 price target, providing a prominent analyst endorsement that can attract momentum and institutional buyers. Read More.
• Positive Sentiment: Multiple major shareholders and investors (including Enterprise Associates/NEA‑17, Forest Baskett, Scott Sandell and others) disclosed large purchases (~207,100 shares at ~$11.11 each), signaling strong insider/large‑holder conviction and providing buying support. Read More.
• Positive Sentiment: Corporate update: Korro nominated KRRO‑121 for hyperammonemia, is advancing a GalNAc oligo candidate for AAT deficiency (on track to nominate in Q2 2026), and closed an oversubscribed $85M private placement, which management says extends cash runway into H2 2028 — materially reducing near‑term financing risk. Read More.
• Neutral Sentiment: Revenue for Q4 modestly exceeded expectations ($1.29M vs. ~ $0.42M est.), but the amount is very small relative to R&D and operating burn, so near‑term profit improvement is limited. Read More.
• Negative Sentiment: Quarterly and annual results show heavy write‑downs and operating losses: Q4 EPS was a ($5.32) miss vs. consensus (~($1.93)), and full‑year net loss widened (reported ~$117.3M) driven by non‑cash impairment charges — highlighting high execution risk and potential for volatility if clinical progress stalls. Read More. Read More.

Korro Bio Company Profile

Korro Bio, Inc is a clinical-stage biotechnology company focused on harnessing advanced protein engineering and synthetic biology to develop novel enzyme therapies and live microbial therapeutics. The company’s proprietary platform integrates directed evolution, high-throughput screening and computational design to optimize biological catalysts for a wide range of applications. By combining machine learning with experimental biology, Korro Bio seeks to accelerate the discovery and development of next-generation treatments for rare genetic disorders and complex metabolic diseases.

The company’s pipeline features both engineered enzyme therapeutics and live biotherapeutics.